MIRA-55 Oral Formulation Shows Favorable Brain and Liver Distribution in Preclinical Study
MIRA is trading near its 52-week low of $0.896 (4.6% above the low) on light trading volume (0.3× avg).
Summary
MIRA Pharmaceuticals reported successful formulation results for MIRA-55, an oral non-opioid pain candidate, showing favorable brain and liver distribution in preclinical studies—a step forward in its development for chronic inflammatory pain.
Key Events · Product Development and Regulatory · MIRA
-
Lead Oral Formulation Selected
An optimized oral formulation of MIRA-55 was selected after demonstrating favorable oral bioavailability and sustained systemic exposure in preclinical studies.
-
Brain and Liver Distribution Achieved
Following oral administration, the formulation showed reproducible distribution into brain and liver tissue, supporting its potential for both central and peripheral pain modulation.
-
Builds on Prior Efficacy Data
These pharmacokinetic results add to earlier preclinical studies in which oral MIRA-55 normalized pain and reduced inflammation, outperforming injected morphine.
-
Next Steps: Additional Preclinical Work
The company plans to continue evaluating tissue exposure, pharmacodynamic activity, and therapeutic efficacy as MIRA-55 advances through further preclinical development.
Analysis · MIRA · Life Sciences
Positive preclinical pharmacokinetic results for the lead oral formulation of MIRA-55, a non-opioid candidate targeting chronic inflammatory pain, were announced by MIRA Pharmaceuticals. The optimized formulation delivered favorable oral bioavailability and reproducible distribution into brain and liver tissue—key sites for central and peripheral pain mechanisms. These findings build on earlier efficacy data in which MIRA-55 outperformed injected morphine in a pain model. The update strengthens the development package for a compound that the DEA does not classify as a controlled substance and supports progression toward additional preclinical studies. For a micro-cap company trading near its 52-week low, pipeline progress of this nature represents a meaningful de-risking event that could improve sentiment around the company's ability to advance its non-opioid pain portfolio.
At the time of this filing, MIRA was trading at $0.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.7M. The 52-week trading range was $0.90 to $2.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.